1. Ferraris CM, D'Avanzo PA, Knox J, Jennings L, et al.
   Parallel declines in antiretroviral therapy adherence by dried blood spot and electronic monitoring in Cape Town, South Africa.
   AIDS 2026;40:1402-1405.
   


2. Davies CR, Webber TR, Dirajlal-Fargo S, Funderburg NT, et al.
   Early-treated children with perinatal HIV show elevated monocyte activation into late childhood.
   AIDS 2026;40:1399-1402.
   


3. Spire B.
   Pre-exposure prophylaxis surfing: rethinking partner-dependent HIV prevention strategies among MSM.
   AIDS 2026;40:1397-1398.
   


4. Falconer J, Adams J, Molloy S, Mupeli K, et al.
   Under pressure: a call to increase access to spinal manometers as a critical component of the management of cryptococcal meningitis.
   AIDS 2026;40:1219-1224.
   


5. Chi BH, Kacanek D, Brown E, Amico KR, et al.
   Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum.
   AIDS 2026.
   


6. O'Brien L, Cross S, Wongkalasin N, Hill A, et al.
   Global analysis of pre-exposure prophylaxis to need ratios in 2025.
   AIDS 2026.
   


7. Willemstein IJM, Heijne JCM, Yap K, Illidge J, et al.
   Next step after PrEP: HIV prevention pathways among former PrEP users disengaged from care.
   AIDS 2026.
   


8. McGuinty M, Giguere P, Angel JB.
   Cabotegravir/rilpivirine in pregnancy: early insights from clinical practice.
   AIDS 2026.
   


9. Sumner T, Clark RA, Prys-Jones TO, Bakker R, et al.
   New tuberculosis vaccines for people with HIV.
   AIDS 2026.
   


10. Bhattacharjee M, Phillips N, Schrieff-Brown L, Hoare J, et al.
    HIV-associated neurocognitive disorders, among adolescents with HIV in India.
    AIDS 2026.
    


11. Irwin S, Elliott J, Li F, Ruiz P, et al.
    Altered bile acid metabolism in people with HIV correlates with systemic and intestinal inflammation.
    AIDS 2026.
    


12. Griesel R, Nunez SA, Cordova E, Perez Rios AM, et al.
    Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
    Clin Infect Dis 2026.
    


13. .
    Correction to: A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017.
    Clin Infect Dis 2026.
    


14. Anderer S.
    ACOG Releases New HIV Screening and Prevention Guidelines.
    JAMA 2026.
    


15. .
    Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: Research Summary.
    JAMA 2026.
    


16. Woods J, Lebina L, Moller K, Venter WDF, et al.
    Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.
    JAMA 2026.
    


17. Lee TY, Onukwugha E, Johnson A, Cassidy-Stewart H, et al.
    Harnessing Pharmacy Claims to Strengthen the HIV Care Continuum: Results from the AdhereP4 Program.
    J Acquir Immune Defic Syndr 2026.
    


18. Otto M, Dobra A, Okango E, Tram KH, et al.
    Brief report: Aging of the HIV epidemic in a longitudinal population cohort and its implications for the understanding of long-term HIV prevalence trends.
    J Acquir Immune Defic Syndr 2026.
    


19. Wang Y, Gornalusse GG, Bhatt U, Siegel DA, et al.
    Distinct Transcriptomic Profiles in ART-Treated People with HIV Are Associated with NF-kappaB-regulated Gene Expression and Inflammatory Cytokine Signatures.
    J Acquir Immune Defic Syndr 2026.
    


20. Alonso-Rodriguez N, Edlund IH, Aass HCD, Sopegno C, et al.
    CD4+ T cell markers associated with Treatment Outcomes in Tuberculosis: A Sub-analysis of a Phase IIB Trial of Acetylsalicylic acid and Ibuprofen as Adjunctive Therapy.
    J Infect Dis 2026.
    


21. Timonina V, Popadin K, Ait Oumelloul M, Calmy A, et al.
    Epidemiology and Clinical Impact of Clonal Hematopoiesis in People with HIV.
    J Infect Dis 2026.
    


22. Huang X, Wang Z, Wang Y, Song X, et al.
    Metabolic Mechanisms of INSTI-Associated Weight Gain: A Multi-Omics Study in Male People with HIV.
    J Infect Dis 2026.
    


23. Frasca F, Maddaloni L, D'Auria A, Fracella M, et al.
    SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV.
    J Med Virol 2026;98:e71067.
    


24. Man S, Affandi AJ, Brink HJ, van Hamme JL, et al.
    Siglec-1-targeted nanobodies restrict HIV-1 transmission and infection of dendritic cells.
    J Virol 2026.
    


25. Pinkevych M, Docken SS, Wu Y, Schlub T, et al.
    The rebound-initiating viral reservoir (RIVR) in SIV/SHIV infection is dominated by plasma virus sequences present at the time of ART initiation.
    J Virol 2026.
    


26. Dwivedi S, Kar S, Horton AP, Gollihar JD, et al.
    ViralMap: predicting features in viral proteins from primary sequence.
    J Virol 2026.
    


27. King HAD, Subra C, Tourtellott E, Swafford I, et al.
    Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.
    J Virol 2026.
    


28. Kavanagh MM, Stiglitz JE, Geingos M, Byanyima W, et al.
    The Inequality-Pandemic Cycle - Rethinking Preparedness.
    N Engl J Med 2026.
    


29. Rockstroh JK, Ramgopal MN, Curran Fabregas A, Hedgcock M, et al.
    Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
    N Engl J Med 2026.
    


30. Cohen J.
    A rocky rollout.
    Science 2026;393:450-457.
    

Display articles in

• Abstract format